HBK Investments L P increased its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 968.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 36,800 shares of the biopharmaceutical company’s stock after buying an additional 33,357 shares during the period. HBK Investments L P’s holdings in Regeneron Pharmaceuticals were worth $13,835,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in REGN. Ark Investment Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 78.8% during the second quarter. Ark Investment Management LLC now owns 1,234 shares of the biopharmaceutical company’s stock worth $606,000 after buying an additional 544 shares during the period. Andra AP fonden increased its stake in shares of Regeneron Pharmaceuticals by 120.0% during the third quarter. Andra AP fonden now owns 2,200 shares of the biopharmaceutical company’s stock worth $984,000 after buying an additional 1,200 shares during the period. Chicago Equity Partners LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $675,000. Bessemer Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 952.4% during the third quarter. Bessemer Group Inc. now owns 663 shares of the biopharmaceutical company’s stock worth $297,000 after buying an additional 600 shares during the period. Finally, Global X MANAGEMENT CO LLC increased its stake in shares of Regeneron Pharmaceuticals by 10.7% during the third quarter. Global X MANAGEMENT CO LLC now owns 1,334 shares of the biopharmaceutical company’s stock worth $596,000 after buying an additional 129 shares during the period. Hedge funds and other institutional investors own 66.40% of the company’s stock.
Shares of Regeneron Pharmaceuticals Inc (REGN) opened at $344.55 on Tuesday. The firm has a market capitalization of $37,020.00, a P/E ratio of 26.22, a PEG ratio of 1.07 and a beta of 1.54. Regeneron Pharmaceuticals Inc has a fifty-two week low of $313.53 and a fifty-two week high of $543.55. The company has a quick ratio of 3.18, a current ratio of 3.82 and a debt-to-equity ratio of 0.11.
In related news, Director Joseph L. Goldstein sold 1,000 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $325.60, for a total transaction of $325,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 10.80% of the stock is owned by company insiders.
A number of equities analysts recently issued reports on REGN shares. JPMorgan Chase & Co. upped their price target on Regeneron Pharmaceuticals from $455.00 to $457.00 and gave the company a “neutral” rating in a report on Wednesday, January 24th. Zacks Investment Research downgraded Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, February 5th. Evercore ISI lowered their price target on Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating for the company in a report on Thursday, November 16th. Argus lowered their price target on Regeneron Pharmaceuticals from $540.00 to $470.00 and set a “buy” rating for the company in a report on Thursday, December 28th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $522.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, February 7th. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $449.49.
ILLEGAL ACTIVITY WARNING: “HBK Investments L P Purchases 33,357 Shares of Regeneron Pharmaceuticals Inc (REGN)” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2018/03/13/hbk-investments-l-p-purchases-33357-shares-of-regeneron-pharmaceuticals-inc-regn.html.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.